Abstract
Mantle cell lymphoma (MCL), being a kind of aggressive non-Hodgkin's lymphoma (NHL), accounts for 6%-8% of NHL in adults which is characterized by malignant B cell infiltration of lymph node, gastrointestinal tract and bone marrow. MCL commonly responds to initial therapy but inevitably occurs relapse and drug resistance. The study on MCL in the 58th American Society of Hematology Annual Meeting has covered many aspects such as basic research, clinical treatment and new drug research. The development of novel mouse model and the exploration of signaling pathways provide a basis for the improvement of MCL pathogenesis and new drug research. VcR-CVAD, VCR and some other chemotherapy regimens designed for different patients have showed satisfactory results. New drugs such as inhibitors of CDK, PI3K and bcl-2 in initial clinical trials are also promising. IACS-010759 and other small molecules provide new directions for the treatment of MCL. Key words: Mantle cell lymphoma; American Society of Hematology Annual Meeting
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call